Key facts
- InsituGen’s last known valuation is $4.5M (Mar 2024).
- It has raised $3.2M; the latest was Later Stage VC ($420K) in Aug 2025.
- Notable investors include Enterprise Angels, Aspire NZ Seed Fund, Booster Innovation Fund, Pacific Channel.
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for InsituGen
- ·The full record, as it builds
Funding rounds
No funding rounds for InsituGen are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About InsituGen
Developer of bioassay technology designed to detect androgen and estrogen bioactivity without targeting specific compounds. The company platform offers cell-free bioassays for use in anti-doping, sports, wellness supplement testing, and companion animal wellness, enabling clients with accurate, fast, and sensitive hormone activity detection across various applications.
- Sector
- Healthcare
- HQ
- Dunedin, New Zealand
- Founded
- 2020
- Employees
- 11
- Website
- insitugen.com/
- Ownership
- Privately Held (backing)
InsituGen doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in InsituGen shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on InsituGen in its N-PORT filings yet. We sweep new filings monthly.